2022
Poor reproducibility of percentage of normally shaped sperm using the World Health Organization Fifth Edition strict grading criteria
Baker KC, Steiner AZ, Hansen KR, Barnhart KT, Cedars MI, Legro RS, Diamond MP, Krawetz SA, Usadi R, Baker VL, Coward RM, Sun F, Wild R, Masson P, Smith JF, Santoro N, Zhang H, Network R. Poor reproducibility of percentage of normally shaped sperm using the World Health Organization Fifth Edition strict grading criteria. F&S Reports 2022, 3: 110-115. PMID: 35789726, PMCID: PMC9250115, DOI: 10.1016/j.xfre.2022.03.003.Peer-Reviewed Original ResearchFertility centerCore laboratoryStrict morphologySecondary cohort analysisPlacebo-controlled trialSame semen sampleMultisite clinical trialLower reference limitSemen samplesInfertility trialsClinical trialsFertility laboratoriesCohort analysisCutoff valueEffect of antioxidantsReference limitsInterobserver agreementCentral laboratoryModerate agreementSemen valuesLack of correlationTrialsGrading criteriaMale fertilityCenter Laboratory
2021
The relationship of plasma antioxidant levels to semen parameters: the Males, Antioxidants, and Infertility (MOXI) randomized clinical trial
Knudtson JF, Sun F, Coward RM, Hansen KR, Barnhart KT, Smith J, Legro RS, Diamond MP, Krawetz SA, Zhang H, Usadi R, Baker VL, Santoro N, Steiner AZ. The relationship of plasma antioxidant levels to semen parameters: the Males, Antioxidants, and Infertility (MOXI) randomized clinical trial. Journal Of Assisted Reproduction And Genetics 2021, 38: 3005-3013. PMID: 34455507, PMCID: PMC8609082, DOI: 10.1007/s10815-021-02301-2.Peer-Reviewed Original ResearchConceptsPlasma antioxidant levelsLive birthsClinical trialsSemen parametersAntioxidant levelsVitamin ERank sum testSecondary analysisClinical outcomesNormal rangeBaseline plasma valuesVitamin E levelsWilcoxon rank sum testMale fertilityConclusionsAmong menPrimary endpointDNA fragmentationResultsAt baselineSerum levelsFertility centerE levelsMethodsThis studyMale infertilityFertility outcomesPlasma values
2020
Factors associated with study protocol adherence and bio banking participation in reproductive medicine clinical trials and their relationship to live birth
Engmann L, Sun F, Legro RS, Diamond MP, Zhang H, Santoro N, Bartlebaugh C, Dodson W, Estes S, Ober J, Brzyski R, Easton C, Hernandez A, Leija M, Pierce D, Robinson R, Awonuga A, Cedo L, Cline A, Collins K, Krawetz S, Puscheck E, Singh M, Yoscovits M, Barnhart K, Coutifaris C, Lecks K, Martino L, Marunich R, Snyder P, Alvero R, Comfort A, Crow M, Schlaff W, Casson P, Hohmann A, Mallette S, Christman G, Ohl D, Ringbloom M, Tang J, Bates G, Mason S, DiMaria N, Usadi R, Lucidi R, Rhea M, Baker V, Turner K, Trussell J, DelBasso D, Huang H, Li Y, Makuch R, Patrizio P, Sakai L, Scahill L, Taylor H, Thomas T, Tsang S, Yan Q, Zhang M, Haisenleder D, Lamar C, DePaolo L, Herring A, Redmond J, Thomas M, Turek P, Wactawski-Wende J, Rebar R, Cato P, Dukic V, Lewis V, Schlegel P, Witter F. Factors associated with study protocol adherence and bio banking participation in reproductive medicine clinical trials and their relationship to live birth. Human Reproduction 2020, 35: 2819-2831. PMID: 33190149, PMCID: PMC8453415, DOI: 10.1093/humrep/deaa232.Peer-Reviewed Original ResearchConceptsPolycystic ovary syndromeClinical trial protocolMedicine clinical trialsU10 HD055942U10 HD38998Baseline characteristicsTrial protocolClinical trialsLive birthsPolycystic Ovary Syndrome IIU10 HD38992U10 HD39005U10 HD27049STUDY FUNDING/COMPETINGMultiple Intrauterine GestationsStudy protocol adherenceUS multicenter trialRegular ovulatory cyclesClinical trial findingsPolycystic ovarian morphologyPARTICIPANTS/MATERIALSROLE OF CHANCELower household incomeAfrican AmericansAspects of adherence
2019
Lower prevalence of non–cavity-distorting uterine fibroids in patients with polycystic ovary syndrome than in those with unexplained infertility
Huang H, Kuang H, Sun F, Diamond MP, Legro RS, Coutifaris C, Alvero R, Robinson RD, Casson PR, Christman GM, Hansen KR, Santoro N, Eisenberg E, Zhang H, Network E. Lower prevalence of non–cavity-distorting uterine fibroids in patients with polycystic ovary syndrome than in those with unexplained infertility. Fertility And Sterility 2019, 111: 1011-1019.e1. PMID: 30926125, PMCID: PMC6487215, DOI: 10.1016/j.fertnstert.2019.01.020.Peer-Reviewed Original ResearchConceptsPolycystic ovary syndromeUnexplained infertilityUterine fibroidsLow prevalenceOvary syndromeDifferent body mass index (BMI) groupsBody mass index groupsHigher body mass indexHigher total testosteroneNormal uterine cavityAssessment-insulin resistanceBody mass indexRandomized clinical trialsCurrent alcohol usersPrevalence of womenTotal testosteroneCurrent smokersInfertile womenLarge fibroidsMass indexInfertile patientsInsulin resistanceUterine cavityClinical trialsLower percentage